These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24822232)

  • 1. Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.
    Mikhail M; Sallam A
    Med Hypothesis Discov Innov Ophthalmol; 2013; 2(4):113-20. PubMed ID: 24822232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review and update of intraocular therapy in noninfectious uveitis.
    Sallam A; Taylor SR; Lightman S
    Curr Opin Ophthalmol; 2011 Nov; 22(6):517-22. PubMed ID: 21897242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN
    Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C
    J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
    Arcinue CA; Cerón OM; Foster CS
    J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in corticosteroid therapy for uveitis.
    Taylor SR; Isa H; Joshi L; Lightman S
    Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis.
    Park JG; Callaway NF; Ludwig CA; Mahajan VB
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100859. PubMed ID: 32793845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
    Drugs R D; 2005; 6(2):116-9. PubMed ID: 15777105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant - A Case Report.
    Meira J; Madeira C; Falcão-Reis F; Figueira L
    Ophthalmol Ther; 2019 Dec; 8(4):635-641. PubMed ID: 31506865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
    Sanford M
    Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
    Weber LF; Marx S; Auffarth GU; Scheuerle AF; Tandogan T; Mayer C; Khoramnia R
    J Ophthalmic Inflamm Infect; 2019 Jan; 9(1):3. PubMed ID: 30694420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial.
    Couret C; Poinas A; Volteau C; Riche VP; Le Lez ML; Errera MH; Creuzot-Garcher C; Baillif S; Kodjikian L; Ivan C; Le Jumeau de Kergaradec LM; Chiffoleau A; Jobert A; Jaulin J; Biron L; Hervouet E; Weber M
    Trials; 2020 Feb; 21(1):159. PubMed ID: 32041669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
    Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluocinolone acetonide intravitreal implant (Retisert
    Leinonen S; Immonen I; Kotaniemi K
    Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Drugs and New Posterior Delivery Methods in CME.
    de Oliveira Dias JR; Nunes RP; Goldhardt R
    Curr Ophthalmol Rep; 2017 Jun; 5(2):160-168. PubMed ID: 29062594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable intraocular therapies for retinal disorders: progress to date.
    Kuno N; Fujii S
    Drugs Aging; 2010 Feb; 27(2):117-34. PubMed ID: 20104938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis.
    Hikal M; Celik N; Auffarth GU; Kessler LJ; Mayer CS; Khoramnia R
    J Clin Med; 2021 Sep; 10(17):. PubMed ID: 34501414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A cost-effectiveness study of dexamethasone implants in macular edema].
    Lozano López V; Serrano García M; Mantolán Sarmiento C; Pareja Ríos A; Losada Castillo MJ; Cordovés Dorta L; Quijada Fumero E; Virgós Aller T; Bullejos Molina M
    Arch Soc Esp Oftalmol; 2015 Jan; 90(1):14-21. PubMed ID: 25443181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluocinolone acetonide implantable device for diabetic retinopathy.
    Schwartz SG; Flynn HW
    Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.